LILLY

📅 Upcoming

🕒 Recent(90d)

News

• STAT+: Trump administration revises rebate pilot for 340B drug discount program, angering hospitals
  The Trump administration is revising its rebate pilot for the 340B drug discount program, angering hospitals.
  stat · 5h ago
• Lilly and Resilience invest $750M in diabetes and obesity drug device supply
  The investment will expand Resilience’s U.S. capacity to make the KwikPen device Eli Lilly uses to deliver its injectable diabetes and obesity medicines.
  biospace · 6h ago
• Novo's IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%
  Novo Nordisk's IL-6 inhibitor ziltivekimab failed to reduce the risk of cardiovascular events in the late-stage trial, dashing hopes for an edge in the hyper-competitive cardiometabolic space.
  biospace · 7h ago
• STAT+: Up and down the ladder: The latest comings and goings
  From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
  stat · 8h ago
• STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more
  An FDA advisory panel recommended use of an experimental Replimune treatment for advanced melanoma that the agency has rejected twice
  stat · 9h ago
• Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch
  Apnimed has raised $192 million for its upsized IPO, with the proceeds earmarked to fund the launch of its sleep apnea pill.
  fiercebiotech · 18h ago
• Capricor’s data clash and a fugitive in the C-suite
  Is the FDA taking inconsistent approaches to Duchenne drugs? And how will a new batch of drug executives shake up their companies? Find out on the latest episode of "The…
  stat · 1d ago
• J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
  The deal with the buzzy Flagship Pioneering-backed startup makes J&J the latest large drugmaker to bet that the technology might be able to treat autoimmune conditions.
  biopharma_dive · 1d ago
• BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
  Strong quarterly results are prompting Bristol Myers Squibb to lift its 2026 outlook, though the company is facing another delay for key Cobenfy Alzheimer’s data and a pushed-back readout for milve…
  biospace · 1d ago
• AtaiBeckley attracted co-development and royalty offers before $2.8B Lilly deal
  More details have emerged about how the industry’s largest psychedelic biotech buyout came to fruition. In an SEC filing on Thursday morning, AtaiBeckley disclosed some of the play-by-play from its
  endpoints · 1d ago